Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Remimazolam Versus Propofol on Motor Evoked Potentials and Somatosensory Evoked Potentials During Spinal Tumor Surgery: A Randomized Controlled Trial

NCT07901504 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.

NCT NCT07901504 Not yet recruiting Phase 4 190 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07901504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Interventional study, Phase 4, 190 participants (estimated). Lead sponsor Beijing Tsinghua Chang Gung Hospital; China. Primary measure: MEP amplitude preservation ratio during the critical period of tumor manipulation. 3 linked papers.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Remimazolam Versus Propofol on Motor Evoked Potentials and Somatosensory Evoked Potentials During Spinal Tumor Surgery: A Randomized Controlled Trial
Lead sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
February 29, 2028
Enrollment
190 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
Beijing Tsinghua Chang Gung Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Remimazolam-based total intravenous anesthesia Experimental Remimazolam
Show registry wording

Remimazolam is administered for induction of anesthesia at 0.2-0.3 mg/kg intravenously and for maintenance by continuous infusion at 1-2 mg/kg/h, titrated to a bispectral index of 40-60. Depth of anesthesia, analgesia and neuromuscular blockade are standardized identically in both arms: sufentanil 0.3-0.5 micrograms/kg at induction, remifentanil 0.08-0.15 micrograms/kg/min for maintenance, and a single dose of rocuronium 0.6 mg/kg at induction with no intraoperative top-up. Core temperature is maintained at 36.0-37.5 degrees Celsius, mean arterial pressure within 10 percent of baseline and not below 80 mmHg, and heart rate between 50 and 100 beats per minute.

Propofol-based total intravenous anesthesia Active comparator Propofol
Show registry wording

Propofol is administered for induction of anesthesia at 1.5-2.5 mg/kg intravenously and for maintenance by continuous infusion at 4-6 mg/kg/h, titrated to a bispectral index of 40-60. Depth of anesthesia, analgesia and neuromuscular blockade are standardized identically in both arms: sufentanil 0.3-0.5 micrograms/kg at induction, remifentanil 0.08-0.15 micrograms/kg/min for maintenance, and a single dose of rocuronium 0.6 mg/kg at induction with no intraoperative top-up. Core temperature is maintained at 36.0-37.5 degrees Celsius, mean arterial pressure within 10 percent of baseline and not below 80 mmHg, and heart rate between 50 and 100 beats per minute.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
MEP amplitude preservation ratio during the critical period of tumor manipulation Intraoperative: from the baseline recording (after induction of anesthesia and before surgical incision) through the end of tumor manipulation
Show registry wording

Mean motor evoked potential (MEP) amplitude of the target muscles recorded during the critical period of tumor manipulation (time points T2 to T4), expressed as a percentage of the baseline (T0) amplitude. Baseline MEP amplitude is recorded after induction of anesthesia and before surgical incision, with a train-of-four ratio of at least 0.9. The primary analysis uses analysis of covariance with adjustment for baseline MEP amplitude, tumor type, tumor level, age and body mass index, under the intention-to-treat principle, with a per-protocol sensitivity analysis. The superiority margin is zero.

Papers

PubMed papers this trial cites; 3 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • PROPOFOL 1 Orange Book patent
    • US 4056635; expires November 1, 1996; assignee Imperial Chemical Industries Limited
  • Remimazolam 11 Orange Book patentsPatent cliff January 13, 2034 (Orange Book patent)
    • US 9827251; expires January 23, 2034; assignee Paion UK Ltd.
    • US 9561236; expires April 30, 2033; assignee Paion UK Ltd.
    • US 10052334; expires November 7, 2031; assignee Paion UK Ltd.
    • US 10195210; expires November 7, 2031; assignee Paion UK Ltd.
    • US 10342800; expires November 7, 2031; assignee Paion UK Ltd.
    • +6 more patents

Lead sponsor's other trials

Beijing Tsinghua Chang Gung Hospital, most recent start first.